Table 4

Marker levels in patients in remission at month 6, stratified by treatment

Treatment groupGlucocorticoids at month 6
MarkerCYC/AZA (n=60)RTX (n=72)p ValueYes (n=20)No (n=117)p Value
Cytokines
 G-CSF9.56 (4.67;19.6)11.9 (6.81;29.9)0.1921.9 (4.03;36.6)10.2 (6.14;20.7)0.24
 GM-CSF1.38 (<0.98;4.84)1.08 (<0.98;8.33)0.721.18 (<0.98;7.66)1.17 (<0.98;4.68)0.88
 IFNγ<0.49 (<0.49;<0.49)<0.49 (<0.49;<0.49)0.15<0.49 (<0.49;<0.49)<0.49 (<0.49;<0.49)0.84
 IL-6<0.49 (<0.49;0.73)<0.49 (<0.49;0.97)0.350.59 (<0.49;1.18)<0.49 (<0.49;0.73)0.2
 IL-159.93 (3.80;16.4)4.11 (1.77;11.1)0.0014*4.93 (2.11;13.8)5.69 (2.60;13.5)0.69
 IL-1849.7 (27.2;83.3)45.7 (31.1;88.0)0.4945.2 (28.0;128)52.8 (33.1;84.8)0.99
 Osteopontin60.4 (37.7;98.4)50.5 (37.2;72.9)0.07254.4 (38.6;76.4)54.5 (37.6;81.9)0.82
Chemokines
 BCA-138.4 (23.5;60.0)23.9 (16.8;49.2)0.005364.3 (35.1;191)26.9 (17.1;48.2)<0.0001*
 IL-86.40 (3.78;13.0)8.33 (3.49;22.1)0.416.65 (1.76;24.5)7.23 (3.74;14.8)0.72
 IP-1012.6 (7.23;25.4)12.9 (7.68;23.5)0.9816.6 (6.89;30.0)13.1 (7.68;24.2)0.71
 RANTES67.0 (35.5;100)45.3 (29.2;84.2)0.0862.6 (42.8;200)51.1 (30.2;89.5)0.16
 TARC555 (247;2500)700 (393;2500)0.36653 (491;2161)655 (322;2500)0.58
Soluble receptors
 IL-18BP13.0 (6.11;42.4)18.4 (<6.11;65.2)0.512.0 (<6.11;49.3)16.4 (<6.11;55.7)0.51
 sIL-2Rα<2.44 (<2.44;<2.44)<2.44 (<2.44;<2.44)0.19<2.44 (<2.44;<2.44)<2.44 (<2.44;<2.44)0.49
 sIL-6R21.2 (16.0;33.9)22.5 (15.2;32.8)0.8923.0 (15.2;35.7)21.7 (15.5;32.4)0.81
 sTNF-RII2039 (1137;4009)2902 (1470;6569)0.0871528 (978;3285)2524 (1445;5985)0.079
Tissue damage and repair
 ACE190 (127;253)170 (132;260)0.83165 (142;253)180 (129;251)0.91
 bFGF<0.98 (<0.98;11.6)<0.98 (<0.98;4.53)0.883.15 (<0.98;21.0)<0.98 (<0.98;3.75)0.16
 KIM-140.6 (17.3;111)53.9 (15.9;134)0.6728.2 (12.8;119)49.3 (18.5;127)0.3
 MMP-314.9 (11.0;26.0)16.6 (12.9;30.5)0.3929.3 (16.1;43.0)14.9 (11.6;24.0)0.0039
 NGFβ2.30 (0.94;4.21)2.71 (1.35;4.29)0.242.83 (0.75;7.17)2.35 (1.26;4.03)0.58
 PDGF-AB2437 (701;4814)3807 (1463;5864)0.0183049 (748;3967)3295 (886;5610)0.34
 TIMP-1169 (125;233)162 (129;263)0.9212 (144;355)160 (125;224)0.078
Inflammation and vascular injury
 Clusterin78.3 (64.6;91.3)68.2 (57.5;83.8)0.02469.4 (57.2;82.6)73.0 (60.0;86.8)0.26
 CRP0.4 (0.3;1.2)0.5 (0.3;1.0)0.780.5 (0.3;0.8)0.5 (0.3;1.3)0.77
 ESR17 (9;26)11 (7;21)0.03419 (7;28)12 (7;22)0.15
 ICAM-1461 (318;905)607 (356;895)0.25786 (458;1088)490 (329;791)0.14
 NGAL169 (99.9;215)179 (137;287)0.028157 (119;222)174 (130;243)0.61
 PAI-11200 (<977;3733)1645 (<977;5217)0.492545 (<977;5358)1202 (<977;3969)0.38
 VCAM-1155 (116;230)138 (102;216)0.36208 (126;455)145 (107;209)0.027
  • Values are median (IQR). For units, see table 1.

  • *p<0.05 comparing groups, still significant after adjustment for multiple comparisons.

  • BCA-1, CXCL13; bFGF, basic fibroblast growth factor; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte–monocyte colony-stimulating factor; ICAM-1, intercellular adhesion molecule-1; IFN, interferon; IL, interleukin; IL-8, CXCL8; IL-18BP, interleukin 18 binding protein; IP-10, CXCL10; KIM-1, kidney injury molecule-1; MMP-3, matrix metalloproteinase-3; NGAL, neutrophil gelatinase-associated lipocalin; NGFβ, nerve growth factor β; PAI-1, plasminogen activator inhibitor-1; PDGF-AB, platelet-derived growth factor, A and B subunits; RANTES, CCL5; sIL-2R, soluble IL 2 receptor; sIL-6R, soluble IL 6 receptor; sTNF-RII, soluble TNF receptor II; TARC, CCL17; TIMP-1, tissue inhibitor of metalloproteinases-1; VCAM-1, vascular cell adhesion molecule-1.